| Contents |
Overview of HIV prevention programs in developing countries / Michael H. Merson and Julia M. Dayton -- Implications of economic evaluations for national HIV prevention policy makers / David R. Holtgrave and Steven D. Pinkerton -- Statistical issues in HIV prevention / Ron Brookmeyer -- Epidemiological issues in the evaluation of HIV prevention programs / Nancy S. Padian and Stephen C. Shiboski -- Difficult choices, urgent needs: optimal investment in HIV prevention programs / Margaret L. Brandeau -- Methadone treatment as HIV prevention: cost-effectiveness analysis / Harold Pollack -- Costs and benefits of imperfect HIV vaccines: implications for vaccine development and use / Douglas K. Owens, Donna M. Edwards, and Ross D. Shachter -- Harm-reduction in Rome: a model-based evaluation of its impact on the HIV-1 epidemic / Massimo Arcà, Teresa Spadea, Giulia Cesaroni, Marina Davoli, Annette D. Verster, and Carlo A. Perucci -- Evaluating Israel's Ethiopian blood ban / Edward H. Kaplan -- Feeding strategies for children of HIV-infected mothers: modeling the trade-off between HIV infection and non-HIV mortality / James G. Kahn, Elliot Marseille, and Joseph Saba -- Design of HIV trials for estimating external effects / Thomas Philipson -- Estimation of vaccine efficacy for prophylactic HIV vaccines / Ira M. Longini, Jr., Michael G. Hudgens, and M. Elizabeth Halloran -- Health policy modeling: epidemic control, HIV vaccines, and risky behavior / Sally Blower,m Katia Koelle, and John Mills -- Development and validation of a serologic testing algorithm for recent HIV seroconversion / Glen A. Satten, Robert S. Janssen, Susan Stramer, and Michael P. Busch -- Issues in quantitative evaluation of epidemiologic evidence for temporal variability of HIV infectivity / Stephen C. Shiboski and Nancy S. Padian. |
